SEC Form 4 · accession 0001209191-17-054636
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Mauney M.D.
Officer — EVP and Chief Business Officer
Period of report
Sep 28, 2017
Accepted (ET)
Oct 2, 2017 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.19 | Sep 28, 2017 | A | 500,000 | A | — | Sep 28, 2027 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1166,667 shares subject to the option shall vest on each of 9/28/2018 and 9/28/2019; 166,666 shares subject to the option shall vest on 9/28/2020.